Elder Care — Comprehensive Geriatric Assessment and Management — Cost, Top Hospitals & Success Rates | MyMedicPlus

Elder care — encompassing geriatric medicine, gerontological nursing, social care, and family support — addresses the complex, multidimensional health needs of older adults, typically those aged 65 and above. The global population of people aged 65+ is projected to reach 1.6 billion by 2050 (WHO), making geriatric care one of the most important medical disciplines of the 21st century. Older adults are not simply older versions of younger patients — they present with fundamentally different clinical complexity: multiple chronic conditions, polypharmacy, functional impairment, social vulnerability, and the atypical presentation of disease (confusion or falls rather than fever and pain as markers of infection, for example).

The cornerstone of geriatric medicine is the Comprehensive Geriatric Assessment (CGA) — a multidimensional, interdisciplinary diagnostic and therapeutic process that evaluates an older person's medical, functional, cognitive, psychological, social, nutritional, and environmental status. Multiple systematic reviews and meta-analyses (Cochrane review, Ellis et al. 2017) confirm that CGA-delivered care reduces mortality, functional decline, and nursing home admission compared to standard medical care for acutely hospitalised elderly patients — making CGA the highest-level evidence-based geriatric intervention available.

Elder care encompasses a spectrum from proactive assessment and health promotion in community-dwelling older adults, through acute hospital care (orthogeriatrics, acute frailty units), rehabilitation, to long-term care and palliative support. The goals of elder care are not merely disease management but preservation and restoration of function, independence, social engagement, and quality of life — with the individual older person's values, preferences, and life goals at the centre of all planning.

• Geriatric syndromes (the 'giants of geriatrics'): Falls and fear of falling; delirium (acute confusion); dementia; urinary incontinence; frailty and sarcopenia; malnutrition; pressure ulcers; polypharmacy; functional decline; social isolation and loneliness. These syndromes frequently co-exist, interact, and require a geriatric approach rather than single-disease management.
• Polypharmacy management: The average elderly patient takes 5–10 prescribed medications; those in residential care often take 10–15. Polypharmacy increases the risk of drug-drug interactions, adverse drug reactions (ADRs — responsible for 10–15% of hospital admissions in elderly), falls (sedating and blood pressure-lowering drugs), and cognitive impairment (anticholinergic burden). Medicines optimisation — using validated tools such as STOPP/START criteria, the Anticholinergic Cognitive Burden Scale, and Beers Criteria — identifies inappropriate prescribing and drugs to deprescribe. Studies show that systematic polypharmacy review reduces ADRs, falls, and hospital admissions.
• Multimorbidity: 75% of people aged 65+ have two or more chronic conditions simultaneously. Single-disease management guidelines may be contradictory or harmful when applied to the multimorbid elderly patient. Person-centred multimorbidity management prioritises the patient's goals and quality of life, manages conditions in concert rather than in isolation, and regularly reviews whether treatments remain appropriate as patient goals evolve.
• Nutritional problems: Malnutrition affects 15–40% of hospitalised elderly and is associated with increased complications, length of stay, pressure ulcers, and mortality. Assessment with validated tools (MNA — Mini Nutritional Assessment, MUST — Malnutrition Universal Screening Tool) identifies at-risk patients for dietetic intervention. Sarcopenia (loss of muscle mass and strength — a component of frailty) requires protein optimisation (1.2–1.5 g/kg/day) combined with resistance exercise.
• End-of-life and palliative care needs: The majority of people receiving geriatric care will die in older age, often with multiple chronic diseases. Geriatricians and specialist palliative care work collaboratively to manage symptoms, avoid futile interventions, support advance care planning, and ensure dignified, comfortable deaths in the patient's preferred setting (home, hospice, or residential care).

CGA is most beneficial for:

• Acutely hospitalised older adults — Cochrane review (Ellis 2017, 6,000+ patients across 29 RCTs): CGA reduced likelihood of death or functional deterioration at follow-up by 18% and increased likelihood of living at home at 12 months
• Patients presenting with a geriatric syndrome (falls, delirium, functional decline, polypharmacy concerns)
• Pre-operative assessment for major surgery (hip fracture, cardiac surgery, cancer surgery) in patients aged 70+: CGA identifies high-risk patients, guides peri-operative optimisation, and predicts post-operative complications better than standard surgical assessment alone
• Cancer patients aged 70+: ASCO and SIOG (International Society of Geriatric Oncology) recommend geriatric assessment before major cancer treatment — identifies frail patients who may not tolerate standard chemotherapy or surgery doses and may benefit from treatment modifications
• Patients with unexplained functional decline or frequent emergency department attendances
• Patients with suspected frailty (Clinical Frailty Scale score 3+, Fried frailty phenotype criteria)

The multidisciplinary CGA team includes:

• Geriatrician (lead physician)
• Specialist geriatric nurse
• Physiotherapist — gait, balance, falls prevention, mobility rehabilitation
• Occupational therapist — ADL assessment, home environment assessment, adaptive equipment
• Speech and language therapist — dysphagia, communication
• Dietitian — nutritional assessment and management
• Social worker — social circumstances, care package organisation, housing, community support
• Clinical pharmacist — medicines optimisation, polypharmacy review
• Clinical psychologist — cognitive and mental health assessment where needed

Management of Elder Care — Comprehensive Geriatric Assessment and Management is individualised based on disease severity, patient age, comorbidities, and patient values. The geriatric and multidisciplinary team develops a personalised plan incorporating the following evidence-based treatment modalities:

• Conservative and lifestyle-based management: For many presentations, targeted lifestyle modification — including nutritional optimisation, graded physical activity, weight management, alcohol and smoking cessation — forms the foundation of care. Regular specialist monitoring and patient self-management education enable early detection of deterioration and empower patients to actively participate in their treatment.
• Pharmacological therapy: Evidence-based drug therapy tailored to disease mechanism and individual patient profile forms the pharmacological backbone. First-line agents are selected per current international guidelines, with treatment escalated to second-line or combination therapy for inadequate responders. Regular monitoring ensures therapeutic efficacy and detects adverse effects early.
• Procedural and interventional approaches: Where pharmacological management is insufficient or specific structural or functional abnormalities are identified, minimally invasive or interventional procedures are considered. These are performed by experienced geriatric and multidisciplinary specialists at accredited facilities with appropriate pre-procedure preparation and post-procedure monitoring protocols.
• Surgical treatment: Surgery is indicated for patients with advanced disease, complications, or conditions unresponsive to medical management. Modern surgical approaches include laparoscopic, robotic-assisted, and image-guided techniques that minimise operative morbidity and accelerate recovery. Surgical decisions are made following multidisciplinary discussion and informed consent.
• Multidisciplinary team (MDT) care: Complex presentations are managed through an MDT integrating expertise from relevant specialties — geriatric and multidisciplinary medicine, radiology, physiotherapy, nutrition, psychology, and palliative care as appropriate. MDT-driven care demonstrably improves outcomes for complex conditions. Patient and family involvement in MDT planning ensures alignment with individual values.
• Emerging and clinical trial options: Access to investigational treatments through clinical trials at specialist centres offers patients with refractory or high-risk presentations the opportunity to access next-generation therapies under systematic monitoring. Trial eligibility is assessed as part of the MDT plan.

• Mortality reduction: CGA-delivered care in acute hospitals reduces 3-month mortality by approximately 18% vs. standard care (Ellis et al., Cochrane 2017). Geriatric assessment in oncology: CGA-guided treatment decisions reduce treatment-related mortality and toxicity while maintaining oncological outcomes — identifying patients who will not tolerate standard-intensity treatment before it causes harm.
• Reduced institutionalisation: CGA-delivered care increases likelihood of living at home at 12 months vs. residential care or hospital. Home-based CGA programmes for community-dwelling elderly: reduce hospital admissions by 30%, nursing home admissions by 25%, and falls by 20% in high-quality trials. These represent not only quality-of-life benefits but enormous healthcare cost savings.
• Polypharmacy reduction: Systematic medicines review in elderly patients identifies and discontinues an average of 2–3 inappropriate or unnecessary medications per patient. Benefits include: reduced ADRs, improved cognition (reduced anticholinergic burden), lower falls risk (reduced sedating/antihypertensive polypharmacy), reduced medication cost, and improved adherence to remaining medications. STOPP/START-guided deprescribing reduces hospital admissions in elderly patients by 20–30%.
• Functional rehabilitation: Intensive rehabilitation in geriatric wards and intermediate care settings after acute illness or orthopaedic surgery achieves functional recovery to pre-admission level in 50–70% of patients, compared to 30–40% without geriatric-specific rehabilitation. Orthogeriatric co-management of hip fracture patients achieves greater mobility recovery, lower mortality, and shorter hospital stay than orthopaedic care alone.
• Caregiver and family support: Geriatric multidisciplinary teams provide structured support and education to family caregivers — reducing carer burden, improving carer wellbeing, and enabling sustainable community care. Community geriatric outreach services can support complex elderly patients at home, reducing emergency hospital admissions.

• Delirium risk in hospital: Approximately 25–35% of hospitalised elderly patients develop delirium — associated with falls, pressure ulcers, longer hospital stay, increased mortality, and accelerated cognitive decline. Delirium is often preventable: HELP (Hospital Elder Life Program) — non-pharmacological multicomponent intervention including orientation, mobilisation, hydration, vision/hearing optimisation, sleep promotion — reduces delirium incidence by 30–40%. Staff education, appropriate lighting, familiar objects, family presence, and avoiding unnecessary restraints are all elements of delirium prevention.
• Falls and fracture risk in hospital: Fall rate in hospital: 3–5 per 1,000 patient-days; in rehabilitation wards: higher (7–10/1,000). Falls during hospitalisation are associated with hip fracture (the most feared consequence), head injury, loss of confidence, increased length of stay, and delayed rehabilitation. Inpatient falls prevention: non-slip footwear, bed sensor alarms, bed positioned low, call bell within reach, toileting schedules, appropriate mobility aids at bedside, minimise sedating medications.
• Pressure ulcer development: Pressure ulcers (decubitus ulcers) develop in 10–15% of elderly hospital admissions, particularly those immobile, incontinent, malnourished, or with peripheral vascular disease. Prevention: Waterlow/Braden pressure risk assessment on admission; pressure-relieving mattresses (dynamic air mattresses) for high-risk patients; regular repositioning (2-hourly minimum); skin inspection; optimise nutrition; keep skin clean and dry. Once established, pressure ulcers are difficult to heal and carry significant morbidity.
• Diagnostic challenges — atypical presentation: Elderly patients frequently present with atypical symptoms of serious illness: infection presenting as acute confusion (delirium) or falls rather than fever; myocardial infarction presenting without chest pain (silent MI — up to 60% of MIs in very elderly); appendicitis presenting with generalised abdominal distension rather than localised pain; pulmonary embolism presenting as acute confusion. These atypical presentations lead to diagnostic delay and poorer outcomes. High clinical vigilance and low threshold for investigation are required.
• Ethical challenges in elder care: Capacity assessment — determining whether an older person has mental capacity to make decisions (including refusing treatment) is a frequent and complex clinical challenge. When capacity is lacking, best interests decisions must be made in partnership with family, involving the multidisciplinary team and, in some cases, formal ethics consultation or legal proceedings (Court of Protection in UK). Balancing risk management against autonomy — enabling elderly people to take reasonable risks aligned with their values rather than over-medicalising all risk — is a core principle of geriatric medicine.

Treatment response monitoring: Following initiation of Elder Care — Comprehensive Geriatric Assessment and Management, clinical response is assessed at 4–12 weeks. Objective parameters (laboratory values, imaging, functional assessments) and symptom scores are tracked; treatment is adjusted based on response and tolerability.

Regular specialist review: Ongoing management requires specialist appointments every 3–6 months once stable, with more frequent reviews during treatment initiation, dose adjustment, or when complications arise. Each visit includes clinical assessment, medication review, and complication screening.

Long-term monitoring: Annual comprehensive review including laboratory investigations, imaging as indicated, quality-of-life assessment, and screening for disease-related complications. Lifelong healthy lifestyle behaviours and regular check-ins with primary care complement specialist follow-up to ensure continuity of care and early detection of any deterioration.

Elder care costs represent a growing proportion of healthcare expenditure in all ageing societies. Understanding international options helps families plan for the long-term care needs of older relatives:

• India: Geriatric outpatient consultation (including CGA): USD 30–150. Annual geriatric specialist follow-up: USD 200–500. Private nursing home / assisted living: USD 3,000–12,000/year. Memory care home for dementia: USD 5,000–15,000/year. Skilled home nursing care: USD 2,000–8,000/year. Physiotherapy and rehabilitation (home-based, 3×/week): USD 50–200/month. Day care centres for elderly: USD 100–400/month. Increasing availability of certified geriatric care services in Indian metro cities (Mumbai, Delhi, Bengaluru, Chennai, Hyderabad). Apollo ElderCare, Portea Medical, and NGO programmes provide community geriatric services. Telemedicine geriatric consultations increasingly available for rural and diaspora families.
• Southeast Asia (Thailand, Malaysia, Singapore): Growing medical tourism for elder care. High-quality assisted living: USD 1,500–5,000/month in Thailand; USD 3,000–8,000/month in Singapore. Specialist geriatric services at Bangkok International Hospital, Bumrungrad, Gleneagles Singapore.
• United Kingdom: NHS provides free acute hospital care including geriatric assessment. Community nursing, physiotherapy, and occupational therapy free on NHS (GP referral). Social care means-tested (assessed by local authority): nursing home costs average GBP 40,000–60,000/year (covered by council if assets <£23,250 threshold in England). Residential care: GBP 25,000–40,000/year.
• United States: Skilled nursing facility (SNF): USD 80,000–100,000/year. Memory care facility: USD 60,000–120,000/year. Home health aide: USD 35,000–60,000/year (10 hours/day). Assisted living: USD 40,000–70,000/year. Medicare covers short-term skilled nursing only; Medicaid covers long-term nursing home for eligible low-income individuals. Long-term care insurance, if purchased in advance, covers a significant portion of these costs.

Alternative or complementary approaches may be considered for patients unsuitable for standard Elder Care — Comprehensive Geriatric Assessment and Management, preferring less intensive treatment, or seeking additional options alongside conventional care:

• Watchful waiting / active surveillance: For patients with mild or stable presentations, a period of active monitoring with regular specialist review may defer treatment. This approach is appropriate only when disease trajectory is slow and quality of life is maintained, with clear pre-defined triggers for initiating active treatment.
• Evidence-based complementary approaches: Structured exercise programmes, dietary interventions, mindfulness-based stress reduction, sleep optimisation, and physiotherapy may complement conventional treatment or provide symptomatic benefit. All complementary approaches should be discussed with the treating specialist to ensure no interactions with ongoing treatments.
• Alternative specialist or second opinion: Patients who have not responded to initial treatment may benefit from referral to a specialist with higher subspecialty expertise or a tertiary centre with access to advanced techniques and clinical trials. A formal second opinion from an experienced specialist is always appropriate before major treatment decisions.
• Clinical trial participation: For refractory or advanced presentations, clinical trials at specialist centres offer access to investigational therapies not yet in routine use — including novel pharmacological agents, targeted biologics, and innovative procedures. Trial costs for experimental components are typically borne by the sponsor.
• Palliative and supportive care: When curative or disease-modifying treatment is not appropriate or desired, specialist palliative care maximises quality of life through expert symptom control, psychological and spiritual support, and coordinated care. Modern palliative medicine can be delivered alongside active treatment at any disease stage and consistently improves patient wellbeing.